In a clinical trial for cannabis use disorder, higher baseline depression predicted less cannabis abstinence during treatment, and depressive symptoms preceded increased cannabis use in the following month.
Clinicians treating cannabis use disorder, mental health professionals addressing dual diagnoses, and researchers studying the depression-cannabis relationship.
Depressive symptoms preceded increased cannabis use, not the reverse
What the researchers found
N-acetylcysteine did not reduce depressive symptoms compared to placebo. Higher baseline depression was associated with decreased abstinence throughout treatment, with a significant gender interaction suggesting this was particularly true for women. Cross-lagged models showed depressive symptoms preceded increased cannabis use, but not the reverse.
Why it matters
The directional finding (depression leads to more cannabis use, but not vice versa) suggests treating depression could improve cannabis cessation outcomes, and that women may need particular attention in this regard.
The numbers in context
302 adults with cannabis use disorder. 12-week trial. NAC did not differ from placebo on depression. Higher baseline depression predicted decreased abstinence. Gender interaction was significant, with stronger effects in females.
How the study worked
Secondary analysis of a multi-site RCT (N=302) comparing 2,400 mg/day NAC vs placebo for cannabis use disorder over 12 weeks. All participants received contingency management. Depression measured by HADS. Cannabis use verified by urinary cannabinoid levels.
What this study cannot tell us
Secondary analysis, so the study was not originally designed or powered to test these depression-related questions. Depression was measured with a screening tool (HADS), not a diagnostic interview. Predominantly male sample limits gender-related conclusions.
How to read the evidence
Secondary analysis from a well-designed multi-site RCT with objective cannabis measures, though not originally designed for these questions.
When this study was published
2020 publication from a NIDA Clinical Trials Network study. Contributes to understanding the temporal relationship between depression and cannabis use.
The bigger picture
This study challenges the self-medication hypothesis in both directions: cannabis use did not appear to worsen depression, but depression did drive increased cannabis use, particularly in women.
Questions still open
- Would directly treating depression alongside cannabis use disorder improve cessation outcomes? Why might the depression-cannabis link be stronger in women? Would different antidepressant approaches combined with CUD treatment be more effective?
Common questions
Did NAC help with depression in cannabis users?
Does cannabis use cause depression?
Read the original research
Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder.
Psychopharmacology, 237(2), 479-490
Citation
Tomko, Rachel L; Baker, Nathaniel L; Hood, Caitlyn O; Gilmore, Amanda K; McClure, Erin A; Squeglia, Lindsay M; McRae-Clark, Aimee L; Sonne, Susan C; Gray, Kevin M. (2020). Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder.. Psychopharmacology, 237(2), 479-490. https://doi.org/10.1007/s00213-019-05384-z
Explore the wider topic
- LGBTQ+ and Cannabis: Higher Use Rates and Recovery
- Cannabis-Induced Psychosis: What It Is, Who's at Risk, and What to Do
- BetterHelp, Cerebral, and Online Therapy: Honest Review
- Quitting Weed with ADHD: Why It Is Harder and What Actually Helps
- Quitting Weed with Depression: What You Need to Know
- Quitting Weed with PTSD: A Practical Guide
- Self-Medicating with Weed: Why It Works Until It Doesn't
- Weed and OCD: Self-Medicating Intrusive Thoughts
- Weed and PTSD: What the Research Actually Shows
- Weed and Childhood Trauma: ACEs, Self-Medication, and the Path to Real Healing
- Weed and Suicidal Thoughts: What You Need to Know